Advanced pancreatic cancer treated with camrelizumab combined with apatinib: A case report

Figure 3 Magnetic resonance imaging of liver metastasis during different anticancer treatment regimens. A: On November 23, 2022, an enhanced abdominal magnetic resonance imaging (MRI) revealed a nodular lesion in the right posterior lobe of the liver, with a maximum cross-section of 2.0 cm × 1.9 cm. The lesion exhibited annular enhancement, indicative of a metastatic lesion; B: On February 21, 2023, follow-up MRI revealed a decrease in the size of the nodular lesion to 1.2 cm × 0.9 cm, with persistent annular enhancement; C: On April 11, 2023, MRI revealed an increase in the size of the lesion to 2.0 cm × 1.9 cm, maintaining annular enhancement; D: On July 5, 2023, the lesion was observed to have decreased in size again, measuring 1.4 cm × 1.0 cm, with annular enhancement still present; E: On October 18, 2023, the MRI showed a further reduction in lesion size to 0.9 cm × 0.6 cm, and no enhancement was noted; F: On January 12, 2024, the final MRI revealed no change in lesion size, remaining at 0.9 cm × 0.6 cm, and no enhancement was observed.